Intra-Cellular Therapies IncNASDAQ:ITCI
- LAST PRICE75.7200
- TODAY'S CHANGE (%)1.0200 (1.3655%)
- Bid / Lots75.6500/ 2
- Ask / Lots75.8200/ 4
- Open / Previous Close75.1200 / 74.7000
- Day Range
- 52 Week Range
- Volume102,277
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ITCI |
|---|---|---|
| 09:32 ET | 4057 | 75.385 |
| 09:34 ET | 100 | 74.81 |
| 09:36 ET | 200 | 75.12 |
| 09:38 ET | 100 | 75.18 |
| 09:39 ET | 100 | 74.81 |
| 09:41 ET | 100 | 74.96 |
| 09:43 ET | 500 | 74.98 |
| 09:45 ET | 25000 | 74.615 |
| 09:48 ET | 1800 | 75.25 |
| 09:50 ET | 400 | 75.075 |
| 09:52 ET | 200 | 75.065 |
| 09:54 ET | 800 | 75.03 |
| 09:56 ET | 100 | 74.87 |
| 09:57 ET | 1300 | 75.59 |
| 09:59 ET | 2109 | 76.12 |
| 10:01 ET | 1540 | 76 |
| 10:03 ET | 200 | 75.79 |
| 10:06 ET | 200 | 75.795 |
| 10:08 ET | 100 | 75.96 |
| 10:10 ET | 200 | 75.79 |
| 10:12 ET | 100 | 75.88 |
| 10:14 ET | 881 | 75.985 |
| 10:15 ET | 200 | 75.955 |
| 10:19 ET | 493 | 76 |
| 10:21 ET | 238 | 76 |
| 10:24 ET | 1029 | 75.9 |
| 10:26 ET | 1204 | 75.85 |
| 10:32 ET | 7331 | 75.68 |
| 10:33 ET | 1214 | 75.93 |
| 10:35 ET | 300 | 75.99 |
| 10:37 ET | 2862 | 75.91 |
| 10:39 ET | 300 | 75.97 |
| 10:42 ET | 200 | 75.9 |
| 10:44 ET | 100 | 75.87 |
| 10:46 ET | 1667 | 75.77 |
| 10:48 ET | 800 | 75.75 |
| 10:50 ET | 719 | 75.42 |
| 10:51 ET | 100 | 75.52 |
| 10:53 ET | 600 | 75.37 |
| 10:55 ET | 901 | 75.42 |
| 11:02 ET | 600 | 75.35 |
| 11:04 ET | 122 | 75.37 |
| 11:06 ET | 400 | 75.505 |
| 11:08 ET | 900 | 75.425 |
| 11:09 ET | 800 | 75.43 |
| 11:11 ET | 200 | 75.395 |
| 11:13 ET | 200 | 75.5 |
| 11:20 ET | 500 | 75.47 |
| 11:22 ET | 100 | 75.55 |
| 11:26 ET | 300 | 75.5 |
| 11:27 ET | 531 | 75.71 |
| 11:33 ET | 900 | 75.69 |
| 11:36 ET | 100 | 75.75 |
| 11:42 ET | 100 | 75.79 |
| 11:44 ET | 200 | 75.72 |
Sep 16, 2024
DJ Intra-Cellular Therapies Price Target Maintained With a $130.00/Share by Cantor Fitzgerald, from 12:00PM ET on Monday Sep 16, 2024 by Dow Jones
12:00PM ET on Monday Sep 16, 2024 by Dow Jones
Sep 9, 2024
DJ S&P 500 Futures Climb In Premarket Trading; Summit Therapeutics, Palantir Technologies Lead, from 7:30AM ET on Monday Sep 09, 2024 by Dow Jones
7:30AM ET on Monday Sep 09, 2024 by Dow Jones
Sep 6, 2024
DJ Intra-Cellular Therapies Raised to Overweight From Neutral by Piper Sandler, from 8:30AM ET on Friday Sep 06, 2024 by Dow Jones
8:30AM ET on Friday Sep 06, 2024 by Dow Jones
Aug 28, 2024
Intra-Cellular Therapies to Present at Three Upcoming Investor Conferences, from 8:00AM ET on Wednesday Aug 28, 2024 by Dow Jones
8:00AM ET on Wednesday Aug 28, 2024 by Dow Jones
Aug 21, 2024
DJ Intra-Cellular Therapies Is Maintained at Overweight by JP Morgan, from 10:24AM ET on Wednesday Aug 21, 2024 by Dow Jones
10:24AM ET on Wednesday Aug 21, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Intra-Cellular Therapies Inc | 7.9B | -87.8x | --- |
Tempus AI Inc | 7.9B | -6.5x | --- |
Legend Biotech Corp | 9.1B | -32.3x | --- |
Halozyme Therapeutics Inc | 7.9B | 23.2x | --- |
Ascendis Pharma A/S | 8.7B | -16.0x | --- |
Ultragenyx Pharmaceutical Inc | 5.3B | -8.2x | --- |
Company Information
Intra-Cellular Therapies, Inc. is a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders. The Company leverages intracellular approach to develop treatments for people living with complex psychiatric and neurologic diseases. The Company’s product, CAPLYTA (lumateperone), is an oral, once daily atypical antipsychotic approved in adults for the treatment of schizophrenia and the treatment of depressive episodes associated with bipolar I or II disorder (bipolar depression) as monotherapy and as adjunctive therapy with lithium or valproate. Its pipeline includes several product candidates in clinical development and additional product candidates in non-clinical testing, such as ITI-1284-ODT-SL program, Phosphodiesterase type I inhibitor (PDE1) program, ITI-333 program, and ITI-1500 Non-Hallucinogenic Psychedelic program. ITI-1284 is a deuterated form of lumateperone, a new chemical entity.
Contact Information
- Headquarters
- 430 East 29th Street, Suite 900NEW YORK, NY, United States 10016
- Phone
- 646-440-9333
- Fax
- 302-655-5049
Executives
- Chairman of the Board, Chief Executive Officer
- Sharon Mates
- President
- Michael Halstead
- Chief Financial Officer, Executive Vice President
- Sanjeev Narula
- Executive Vice President, Chief Medical Officer
- Suresh Durgam
- Executive Vice President, Chief Commercial Officer
- Mark Neumann
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $7.9B |
|---|---|
Revenue (TTM) | $564.5M |
Shares Outstanding | 105.7M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.00 |
EPS | $-0.86 |
Book Value | $6.14 |
P/E Ratio | -87.8x |
Price/Sales (TTM) | 14.0 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -19.93% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
